NBCC made the case in 2008 that accelerated approval for bevacizumab (Avastin®) was lowering the bar on drug approval. There
Read MoreIn mathematical modeling study, investigators find benefits outweigh risks of biennial mammograms for high-risk women in their 40s A study
Read MorePersonalizing Mammography by Breast Density and Other Risk Factors July 5, 2011 The results of an analysis estimating the cost-effectiveness of mammography by age,
Read MoreACS predicts over 290,000 women and men to be diagnosed within situ and invasive breast cancer in 2012 January 6, 2012 The
Read More